This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna Lags Industry in '19: Can Efforts Aid Recovery in 2020?
by Sapna Bagaria
Cigna's (CI) business streamlining and acquisitions are expected to drive growth in 2020.
The Zacks Analyst Blog Highlights: SAP, AbbVie, Sinopec, Cigna and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SAP, AbbVie, Sinopec, Cigna and Intuitive Surgical
Top Stock Reports for SAP, AbbVie & Sinopec
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), AbbVie (ABBV) and Sinopec (SNP).
Cigna to Divest Non-Health Unit, Streamline Operations
by Zacks Equity Research
Cigna (CI) announces sale of its Group Life and Disability business to focus on debt reduction and core business of healthcare.
WellCare Health, Fitbit Collaborate to Aid Diabetes Patients
by Zacks Equity Research
WellCare Health (WCG) and Fitbit team up to encourage Georgia-based WellCare Medicaid members to manage their diabetic condition.
HMO Industry Outlook: Multiple Levers to Drive Growth
by Sapna Bagaria
Aging U.S population, consolidation, use of technology and growing health service businesses provide ample scope for the industry to grow.
Cigna Considers Divesting Its Non-Health Insurance Business
by Zacks Equity Research
Speculations ran rife that Cigna (CI) is on the lookout of a bidder for its non-health insurance arm to streamline in-house operations.
UnitedHealth (UNH) to Buy Diplomat, Expand Pharmacy Services
by Sapna Bagaria
UnitedHealth (UNH) inks an agreement to acquire Diplomat to expand its in-house pharmacy benefit management business.
Here's Why Select Medical (SEM) Stock Looks Attractive
by Sapna Bagaria
Select Medical (SEM) benefits from revenue growth, acquisitions, and strong earnings guidance.
UnitedHealth (UNH) Provides Guidance for 2020, Shares Fall
by Sapna Bagaria
UnitedHealth's (UNH) guidance for 2020 indicates revenue and earnings growth but it is believed to be conservative, leading to a decline in shares.
BioDelivery's Belbuca Sales & Symproic Addition Encouraging
by Zacks Equity Research
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
Is Cigna Corporation (CI) a Solid Value Investor Pick Now?
by Zacks Equity Research
Let's see if Cigna Corporation (CI) stock is a good choice for value-oriented investors right now from multiple angles.
3 Healthcare Stocks to Counter Tech Encroachment
by Sreyoshi Mukherjee
Traditional U.S. healthcare companies are resorting to vertical integration to counter the tech threat.
Healthcare ETF (IHF) Tops in October: 5 Best Stocks
by Sweta Killa
Inside the best performing stocks of the top ETF of October.
Cigna (CI) Q3 Earnings & Revenues Beat Estimates, View Up
by Zacks Equity Research
Cigna (CI) Q3 results reflect higher revenues and membership from Express Scripts merger.
Cigna (CI) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 3.89% and 5.08%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Cigna (CI) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna (CI) Q3 earnings are likely to have benefited from higher contribution across all its segments and effect of share buyback.
Cigna (CI) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Cigna (CI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cigna (CI) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Cigna (CI) closed at $166.88, marking a +1.28% move from the previous day.
Big Bank & Healthcare Earnings, Netflix Q3 Preview & Buy Lululemon Stock - Free Lunch
by Benjamin Rains
Breaking down some of Tuesday's major Q3 earnings results from giants such as JPMorgan Chase and UnitedHealth. A look at what to expect from Netflix's third quarter financials Wednesday. And why Lululemon is a Zacks Rank #1 (Strong Buy) stock...
UnitedHealth (UNH) Q3 Earnings and Revenues Beat, Guidance Up
by Sapna Bagaria
UnitedHealth's (UNH) higher revenues, strength in both segments -- UnitedHealthcare and Optum -- plus membership growth leads to earnings outperformance.
Bleak Near-Term Outlook for Multiline Insurance Industry
by Tanuka De
The Multiline Insurance Industry should benefit from better pricing and a solid capital level. However, a declining rate environment is a concern.
Will UnitedHealth's (UNH) Benefits Business Aid Q3 Earnings?
by Zacks Equity Research
Strength in UnitedHealth's (UNH) health service segment is likely to reflect in Q3 results.
Cigna (CI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Cigna (CI) closed the most recent trading day at $152.40, moving +1.04% from the previous trading session.
Zacks.com featured highlights include: Keurig Dr, Cigna, General Dynamics, Lennar and NCR
by Zacks Equity Research
Zacks.com featured highlights include: Keurig Dr, Cigna, General Dynamics, Lennar and NCR